A Study of ASKG915 in Patients With Selected Advanced Solid Tumors
Phase 1/2
594
about 4.9 years
18+
2 sites in NY, PA
What this study is about
This trial is testing a treatment called ASKG915 to see if it's safe and how well it works in people with advanced solid tumors. The trial will also look at the effects of ASKG915 when combined with other treatments like docetaxel, fruquintinib, paclitaxel + bevacizumab.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive ASKG915
- 2.Take Docetaxel
- 3.Take Fruquintinib
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
bevacizumab, docetaxel, fruquintinib, paclitaxel (Taxane chemotherapy; stabilizes microtubules)
infusion, oral (Oral Capsule), injection, intravenous
Primary: Adverse events(AEs), Dose limiting toxicities (DLTs)
Secondary: Area under the concentration time curve (AUC), Duration of response (DOR), Maximum plasma concentration (Cmax), Objective Response Rate (ORR), Plasma clearance rate (CL), Progression-free survival (PFS)